ArticleJournal of virology1997
Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA.
Article in Journal of virology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 75 citations in OpenAlex.
- Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.Journal of virology · 2020Article
- Recent advances in preclinical model systems for papillomaviruses.Virus research · 2017Review
- Stabilized nanosystem of nanocarriers with an immobilized biological factor for anti-tumor therapy.PloS one · 2017Article
- Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.Antiviral research · 2014Article
- Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.Clinical and vaccine immunology : CVI · 2014Article
- Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Frontiers in cellular and infection microbiology · 2014Review
- Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines.Human vaccines & immunotherapeutics · 2013Review
- Clinical development of Listeria monocytogenes-based immunotherapies.Seminars in oncology · 2012Review
- Animal models of listeriosis: a comparative review of the current state of the art and lessons learned.Veterinary research · 2012Review
- Article
- T cell and APC dynamics in situ control the outcome of vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Article
- Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus.Journal of virology · 2007Article
- Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.Journal of virology · 2006Article
- Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.Nature medicine · 2005Article
- Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity.Infection and immunity · 2005Article
- Listeria-based cancer vaccines that segregate immunogenicity from toxicity.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.Infection and immunity · 2002Article
- Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.Journal of virology · 2002Article
- Listeria pathogenesis and molecular virulence determinants.Clinical microbiology reviews · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Listeria monocytogenes is a gram-positive, facultative intracellular bacterium that enters the cytoplasm of infected cells and spreads directly into neighboring cells without encountering the extracellular environment. Cytoplasmic L. monocytogenes efficiently presents secreted proteins to the major histocompatibility complex class I pathway which can stimulate protective T-cell-mediated immune responses. We have used a cottontail rabbit papillomavirus (CRPV) rabbit model to test the ability of recombinant L. monocytogenes strains secreting the viral E1 protein (E1-rLm) to protect outbred rabbits against CRPV- and CRPV DNA-induced tumors. CRPV infection of outbred rabbits serves as a model for oncogenic papillomaviruses since CRPV-induced papillomas progress with high frequency to malignant carcinoma. Rabbits were vaccinated with wild-type L. monocytogenes or E1-rLm and then challenged with CRPV or viral DNA. In contrast to 0% papilloma regression in control animals, 77% of E1-rLm-vaccinated rabbits generated protective immunity that controlled and induced complete regression of tumors induced by CRPV. Latent viral DNA was not detected at 71% of the papilloma regression sites examined 4.5 months postregression. E1-rLm responder rabbits were completely resistant to papilloma formation from viral DNA. In contrast to controls, peripheral blood mononuclear cells from E1-rLm responder rabbits were able to proliferate in response to in vitro E1 stimulation. These results indicate that E1-rLm immunization generated a systemic anti-CRPV E1 cell-mediated immune response which protected outbred rabbits from tumors induced by CRPV or CRPV DNA challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.